Compare Hasbro, Inc. (HAS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Sanofi SA — how do they compare? Hasbro, Inc. trades at $88.77 (market cap $11.53B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 9.1× Hasbro, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| HAS | SNY | |
|---|---|---|
Market Cap | $11.53B | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $52.34 |
52-Week Low | $70.95 | $41.33 |
Enterprise Value | $13.80B | $121.32B |
Dividend Yield | 3.44% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) surged 8.87% to $88.78, driven by strong Q2 2026 earnings that beat estimates with $1.14 billion revenue (up 16% YoY) and raised full-year guidance. Technicals show bullish momentum near resistance at $85, while fundamentals reveal mixed signals: positive cash flow trends and robust Wizards segment growth contrast with negative net income margins and high debt levels. Analyst sentiment is optimistic, with a consensus price target of $104.75 and no sell ratings among 33 covered analysts.
The outlook is cautiously positive, with Magic: The Gathering fueling growth, but risks include elevated valuation multiples (P/E 25.6, EV/EBITDA 41.99) and persistent profitability challenges. Investors may see upside if execution continues, though leverage and margin pressures warrant monitoring.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
